Page last updated: 2024-12-05

osalmide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Osalmide is a natural product isolated from the marine sponge *Oscarella lobularis*. It exhibits potent anti-inflammatory and anti-cancer activities. The compound has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, and to induce apoptosis in cancer cells. Its unique structure and biological activities make it a promising lead compound for the development of new therapeutic agents. The synthesis of osalmide has been achieved using various approaches, including a total synthesis route. Ongoing research focuses on understanding its mechanism of action and optimizing its pharmacological properties for therapeutic applications.'

osalmide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4602
CHEMBL ID389507
CHEBI ID31938
SCHEMBL ID220088
MeSH IDM0046946

Synonyms (95)

Synonym
AC-1737
osalmid [inn:jan]
osalmide [inn-french]
2-hydroxy-n-(4-hydroxyphenyl)benzamide
osalmida [inn-spanish]
nsc 93960
brn 2941480
einecs 208-385-9
bilocol
oxaphenamidum
osalmidum [inn-latin]
3-13-00-01137 (beilstein handbook reference)
osalmidum
osalmida
89741l759z ,
unii-89741l759z
2-hydroxy-n-(4-hydroxy phenyl)benzamide
salmidochol
n-(p-hydroxyphenyl)salicylamide
oksafenamid
n-(4-hydroxyphenyl)salicylamide
l-1718 ,
benzamide, 2-hydroxy-n-(4-hydroxyphenyl)-
phps
n-(p-hydroxyphenyl)salicylanilide
saryuurin
nsc-93960
526-18-1
4'-hydroxysalicylanilide
nsc93960
n'-salicyloyl-p-aminophenol
salicylanilide, 4'-hydroxy-
enidran
p-hydroxyphenylsalicylamide
dribazil
osalmid
oxaphenamide
wln: qr bvmr dq
driol-labaz
p'-hydroxysalicylanilide
hydroxyphenyl salicylamide
driol
osalmide
oxaphenamid
auxobil
l 1718
bilene
NCGC00160580-01
D01579
osalmid (jan/inn)
CHEMBL389507
oksafenamide
2-hydroxy-n-(4-hydroxyphenyl)benzamide;osalmid
A18844
2-hydroxy-n-(4-hydroxyphenyl)-benzamide
dtxcid8022244
cas-526-18-1
tox21_111914
dtxsid0042244 ,
S3641
AKOS008980445
FT-0603451
osalmid [who-dd]
osalmid [jan]
osalmid [inn]
osalmid [mart.]
osalmid [mi]
SCHEMBL220088
smr004703438
MLS006011715
KS-5271
H-7210
Q-100981
jestmin
wr 17456
li dan feng
kanochol
yoshicol
2-hydroxy-n-(4-hydroxyphenyl)benzamide #
LGCMKPRGGJRYGM-UHFFFAOYSA-N
mfcd00020026
SR-01000945010-1
sr-01000945010
CHEBI:31938
HY-B2116
CS-6242
F14930
n-salicoylaminophenol
CCG-266789
oxaphenamide;4'-hydroxysalicylanilide
NCGC00160580-02
Q27270017
1-methyl-3,4-dihydrospiro[chromene-2,4-piperidin]-4-aminehydrochloride
EN300-7359305
Z69118312

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency14.38180.007215.758889.3584AID624030
TDP1 proteinHomo sapiens (human)Potency31.67680.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency20.78700.000221.22318,912.5098AID743042; AID743053; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency11.22020.01237.983543.2770AID1346984
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.52940.000229.305416,493.5996AID743075; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency20.57610.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.73080.001723.839378.1014AID743083
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency30.61260.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency27.24350.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency29.84930.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID288209Antifungal activity against Aspergillus ficuum MTCC 8184 by serial dilution method2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID288208Antibacterial activity against Escherichia coli MTCC 1652 after 24 hrs2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID409712Inhibition of CD40L, IFN-gamma and IL18 mixture-induced IL6 production in mouse DC-B cells after 18 to 24 hrs by fluorescence immunoassay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Salicylanilides: selective inhibitors of interleukin-12p40 production.
AID409711Inhibition of CD40L, IFN-gamma and IL18 mixture-induced IL12p40 production in mouse DC-B cells after 18 to 24 hrs by fluorescence immunoassay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Salicylanilides: selective inhibitors of interleukin-12p40 production.
AID288206Antibacterial activity against Staphylococcus aureus MTCC 290 after 24 hrs2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID288210Antifungal activity against Aspergillus parasiticus MTCC 8189 by serial dilution method2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID409714Cytotoxicity against CD40L, IFN-gamma and IL18 mixture-stimulated mouse DC-B cells at <100 nM after 18 hrs by CellTiter-Glo assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Salicylanilides: selective inhibitors of interleukin-12p40 production.
AID288207Antibacterial activity against Bacillus subtilis MTCC 2063 after 24 hrs2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (42.11)18.7374
1990's1 (5.26)18.2507
2000's2 (10.53)29.6817
2010's3 (15.79)24.3611
2020's5 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]